Form 4: Calidi Biotherapeutics Director Leftwich Scott Acquires 67,187 Shares of Common Stock

Director Leftwich Scott acquired 67,187 shares of Calidi Biotherapeutics common stock on June 28, 2024, increasing their total holdings to 560,873 shares.

Summary

• On June 28, 2024, Leftwich Scott, a director of Calidi Biotherapeutics, acquired 67,187 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs) granted under the company's 2023 Equity Incentive Plan.
• The RSUs fully vested on the grant date.
• Following the transaction, Leftwich Scott's total beneficial ownership of Calidi Biotherapeutics common stock is 560,873 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.

Key Dates